Physician profile
Joyce E Gentry
NPI 1760971105
$654.98
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $655.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $314.38 | 2021 | |
| Amgen INC. | $87.29 | 2021 | |
| Radius Health, INC. | $73.44 | 2021 | |
| Lilly USA, LLC | $38.30 | 2021 | |
| Janssen Biotech, INC. | $34.76 | 2021 | |
| Ucb, INC. | $27.49 | 2021 | |
| Glaxosmithkline, LLC. | $26.20 | 2021 | |
| Novartis Pharmaceuticals Corporation | $25.88 | 2021 | |
| Biodelivery Sciences International, INC. | $15.47 | 2021 | |
| Abbott Laboratories | $11.77 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joyce Gentry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.